We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Ranbaxy Laboratories, India's largest pharmaceutical company, has received tentative approval from the FDA to manufacture and market generic Risperdal (risperidone oral solution) 1 mg/mL.
Teva Pharmaceutical Industries announced that the FDA has granted final approval for the company's generic Effexor (venlafaxine hydrochloride) tablets, 25 mg, 37.5 mg, 50 mg, 75 mg and 100 mg.
TorreyPines Therapeutics has initiated a Phase I trial of NGX426 (tezampanel), an oral therapy that is intended to treat migraine and chronic pain conditions such as neuropathic pain.
Transition Therapeutics has released 12-week data from an open-label, multicenter Phase I/II trial evaluating the interferon-enhancing product, HCV-I.E.T., in hepatitis C non-responders.
GPC Biotech has initiated a Phase II randomized trial evaluating the company's lead drug candidate, satraplatin, in combination with Tarceva (erlotinib) as a first-line therapy in patients with inoperable advanced non-small-cell lung cancer who are 70 years of age and older.
PDL BioPharma has announced its terlipressin treatment failed to show statistical significance in a Phase III trial of patients with a life-threatening complication of advanced liver disease.